Today I have been let out to my first International Meeting in two years and yep it is in London
Here is a copy of my slides
At the Limits 2021
A
Today I have been let out to my first International Meeting in two years and yep it is in London
Here is a copy of my slides
MD1,
Thanks for this. Covid 19 has taken up too much of your precious time.
– ‘If’ Ixazomib scrubs the brain clean of long lived plasma cells, what will prevent the B cells (including plasma cells) repopulating the CNS?
– What benefits might the patient see eg oligo clonal bands disappear, tissue damage stops eg slowly expanding lesions stop?
– Will Ixazomib kill off all plasma cells in the body or just the plasma cells in the CNS?
– How do we know that the plasma cells in the CNS aren’t just doing what they should be doing ie the anti-bodies they produce are against something in the CNS eg EBV infection?
– Why doesn’t the Sizomus trial have and active comparator (for the progressive patients) eg injectible cladribine?
Thanks for all your work on this. I hope the trial has a positive outcome.
1. For much of last year it was do COVID-19 or do nothing…We have been kicked out of labs. […don’t ask:-(]…This occurred until August his year.
1. If it scrubs the brain it scrubs elsewhere too
2. Unknown…MS stops? MS Slows?, Nothing?
3. Yes see 1.
4. They can be good bad or indifferent…the question what is the balance
5. It is a safety phase I study but a cladribine study is being done by ProfK…I predict lack of success
“I predict lack of success”
For which study?
Hate it when asked questions based on. BillSH
Sorry MD1 I’m not sure what you mean.
Sorry MD1 I’m not sure what you mean.
This is answer to another question
guess:-)
Cladribine CSF study
Hate it when asked questions based on. BillSH
Have seen your slides nice work
In this case report the also use proteasome and anti cd-20 with no results
Only daratumumab had some result
Case Report: Daratumumab in a Patient With Severe Refractory Anti-NMDA Receptor Encephalitis
https://www.frontiersin.org/articles/10.3389/fneur.2020.602102/full?utm_source=F-AAE&utm_medium=EMLF&utm_campaign=MRK_1714167_a0P58000000G0Y2EAK_Neurol_20210831_arts_A
Thanks I was thinking antibody treating brain disease but often anti-NMDA come from having a peripheral cancer (tetratoma)
Question so I can be clear: on slide 15 middle column has title of “Availability to enter C¨NS”, is that the memory B cell or the DMT in the far left column?
It will be the drug. Also sorry about slide with out labels the one with the boxes starting on left we had naive, memory, plasmnlast and plasma cell